Doctors raise red flags over widespread melatonin use in children amid insufficient evidence

Melatonin has become one of the most casually used supplements in households with young children. Parents buy it over the counter, give it before bedtime, and largely consider it harmless because it is natural and widely available. A major scientific review is now pushing back on that assumption, not by declaring melatonin dangerous, but by pointing out that the clinical evidence for using it in typically developing children is thin enough that pediatric specialists are calling for a serious reassessment.

Where the evidence actually holds up

The review draws a clear line between two populations. For children with autism spectrum disorder or ADHD, the data on melatonin is reasonably solid. Multiple controlled trials have found that melatonin reduces the time it takes these children to fall asleep and increases total sleep duration. A 2021 Cochrane review covering children with neurodevelopmental conditions found consistent evidence of benefit, with minimal reported adverse effects over short study periods. For this group, pediatric specialists generally consider melatonin an appropriate option when sleep difficulties are persistent and behavioral interventions have not been sufficient.

The situation is different for neurotypical children. The review found that clinical trials in this population are sparse, often small, and typically short in duration. Most do not follow children for longer than a few weeks, which means there is almost no data on what regular melatonin use does to a developing child's hormonal system over months or years.

How widespread the use has become

Melatonin use among children has climbed sharply over the past decade. In the United States, a study published in JAMA Pediatrics in 2023 found that melatonin use in children and adolescents increased fivefold between 2012 and 2021. In some European countries, pediatric melatonin products are now among the top-selling children's supplements. The rise tracks with increased parental awareness of sleep issues in children and the supplement's accessibility as an unregulated or minimally regulated product in most markets.

The concern pediatric specialists have is not about the occasional use. It is about the normalization of nightly melatonin for children whose sleep problems might respond to behavioral interventions, adjusted bedtime routines, or reduced screen exposure in the evening. When a supplement is easy to buy and generally perceived as safe, the motivation to try other approaches first often disappears.

What the body does with melatonin

Melatonin is a hormone produced by the pineal gland. It signals to the body that it is time to sleep by responding to darkness. In children, the natural surge of melatonin at night is already substantial, typically higher than in adults. Giving supplemental melatonin on top of that natural production adds an external hormonal input to a system that is still maturing.

The doses in many commercial children's products are also higher than what studies have used. A common gummy sold for children contains 1 to 5 milligrams per dose, but research trials have often used doses as low as 0.5 milligrams and found that effective. There is no established safe upper limit for children, and overdose calls to poison control centers related to melatonin in the U.S. increased by 530 percent between 2012 and 2021, according to a 2022 report in the CDC's Morbidity and Mortality Weekly Report.

What the review recommends

The review stops well short of recommending that parents stop using melatonin altogether. What it calls for is a shift in how the medical community approaches the supplement. Pediatricians should be asking about melatonin use during routine visits, asking about dosage and duration, and steering families toward behavioral sleep interventions as the first line of response for typically developing children with sleep difficulties.

The review also calls for longer-term trials in neurotypical children to fill the data gap that currently exists. Without that evidence, clinicians are making recommendations in a vacuum, and parents are making purchasing decisions based on marketing rather than medicine. The researchers specifically noted that regulatory frameworks in many countries have not kept pace with the scale of use, leaving melatonin products for children largely unreviewed for safety at the doses being sold commercially.

Sleep problems in children often have fixable causes

Pediatric sleep specialists point out that most sleep difficulties in healthy children can be traced to behavioral or environmental factors. Inconsistent bedtime routines, evening screen use that suppresses natural melatonin production, caffeine in sodas or energy drinks consumed after school, and anxiety about school or social situations are among the most common drivers. These are addressable without supplementation.

Cognitive behavioral therapy for insomnia, adapted for children, has demonstrated effectiveness in several trials. A 2019 study in the Journal of Clinical Sleep Medicine found that a brief behavioral intervention improved sleep onset time in school-age children by an average of 30 minutes per night, without any pharmacological input. The problem is that behavioral interventions require more time and consistency than a gummy before bed, which is part of why the supplement route has become so popular.